Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Robertson

Showing results (71-80 of 103) with videos related to

Pageof 11
Sort By:
Gynecologic Oncology|October 4, 2021
Corrigendum to 'A state-wide population-based evaluation of cervical cancers arising during opportunistic screening in the United States' [Gynecologic Oncology 159 (2020) 344-353]Rebecca Landy, Christopher Mathews, Michael Robertson, et al.
International Journal of Cancer|December 15, 2019
Impact of screening on cervical cancer incidence: A population-based case-control study in the United StatesRebecca Landy, Peter D Sasieni, Christopher Mathews, et al.
Gynecologic Oncology|September 26, 2020
A state-wide population-based evaluation of cervical cancers arising during opportunistic screening in the United StatesRebecca Landy, Christopher Mathews, Michael Robertson, et al.
Gynecologic Oncology|April 19, 2021
Erratum to 'A state-wide population-based evaluation of cervical cancers arising during opportunistic screening in the United States' [Gynecologic Oncology 159 (2020) 344-353]Rebecca Landy, Christopher Mathews, Michael Robertson, et al.
European Heart Journal|June 12, 2024
Therapy duration and improvement of ventricular function in de novo heart failure: the Heart Failure Optimization studyChristian Veltmann, David Duncker, Michael Doering, et al.
Clinical and Translational Gastroenterology|April 3, 2019
Elbasvir/Grazoprevir in People With Hepatitis C Genotype 1 Infection and Child-Pugh Class B Cirrhosis: The C-SALT StudyIra M Jacobson, Fred Poordad, Roberto Firpi-Morell, et al.
Oncotarget|January 5, 2018
High-dose sitagliptin for systemic inhibition of dipeptidylpeptidase-4 to enhance engraftment of single cord umbilical cord blood transplantationSherif S Farag, Robert Nelson, Mitchell S Cairo, et al.
Gastroenterology|February 15, 2017
Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated AnalysisIra M Jacobson, Eric Lawitz, Paul Y Kwo, et al.
Journal of Gastroenterology|January 19, 2018
The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infectionStefan Zeuzem, Lawrence Serfaty, John Vierling, et al.
The Journal of Infectious Diseases|July 29, 2010
AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core proteinRobert T Schooley, John Spritzler, Hongying Wang, et al.
Pageof 11

Showing results (71-80 of 103) with videos related to

Sort By:
Pageof 11
Gynecologic Oncology|October 4, 2021
Corrigendum to 'A state-wide population-based evaluation of cervical cancers arising during opportunistic screening in the United States' [Gynecologic Oncology 159 (2020) 344-353]Rebecca Landy, Christopher Mathews, Michael Robertson, et al.
International Journal of Cancer|December 15, 2019
Impact of screening on cervical cancer incidence: A population-based case-control study in the United StatesRebecca Landy, Peter D Sasieni, Christopher Mathews, et al.
Gynecologic Oncology|September 26, 2020
A state-wide population-based evaluation of cervical cancers arising during opportunistic screening in the United StatesRebecca Landy, Christopher Mathews, Michael Robertson, et al.
Gynecologic Oncology|April 19, 2021
Erratum to 'A state-wide population-based evaluation of cervical cancers arising during opportunistic screening in the United States' [Gynecologic Oncology 159 (2020) 344-353]Rebecca Landy, Christopher Mathews, Michael Robertson, et al.
European Heart Journal|June 12, 2024
Therapy duration and improvement of ventricular function in de novo heart failure: the Heart Failure Optimization studyChristian Veltmann, David Duncker, Michael Doering, et al.
Clinical and Translational Gastroenterology|April 3, 2019
Elbasvir/Grazoprevir in People With Hepatitis C Genotype 1 Infection and Child-Pugh Class B Cirrhosis: The C-SALT StudyIra M Jacobson, Fred Poordad, Roberto Firpi-Morell, et al.
Oncotarget|January 5, 2018
High-dose sitagliptin for systemic inhibition of dipeptidylpeptidase-4 to enhance engraftment of single cord umbilical cord blood transplantationSherif S Farag, Robert Nelson, Mitchell S Cairo, et al.
Gastroenterology|February 15, 2017
Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated AnalysisIra M Jacobson, Eric Lawitz, Paul Y Kwo, et al.
Journal of Gastroenterology|January 19, 2018
The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infectionStefan Zeuzem, Lawrence Serfaty, John Vierling, et al.
The Journal of Infectious Diseases|July 29, 2010
AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core proteinRobert T Schooley, John Spritzler, Hongying Wang, et al.
Pageof 11